CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells 45,147 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 45,147 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $4.76, for a total value of $214,899.72. Following the completion of the sale, the director directly owned 2,579,998 shares of the company’s stock, valued at approximately $12,280,790.48. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

CAMP4 Therapeutics Trading Up 0.4%

Shares of CAMP traded up $0.02 during mid-day trading on Friday, hitting $4.48. The company’s stock had a trading volume of 126,663 shares, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a 1-year low of $1.41 and a 1-year high of $7.75. The firm has a market capitalization of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. The firm has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.33.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million during the quarter. As a group, sell-side analysts predict that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current fiscal year.

Analyst Ratings Changes

CAMP has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.56.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently bought and sold shares of CAMP. Bridgeway Capital Management LLC acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics in the second quarter worth $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.